In the past, European countries contributed a great deal to TB research and development, leading to groundbreaking discoveries like the mycobacterial cause of the disease and the 100-year-old the bacillus Calmette-Guérin (BCG) vaccine. However, since the 2018 United Nations High-Level Meeting on TB, high hopes for European investments have not been realized. European Union (EU) member states have failed to contribute their fair share of funding toward the $2 billion needed globally each year to make TB elimination possible within a generation.
Treatment Action Group (TAG) released a brief outlining the pathway the EU can take to scale up support for TB research and development (R&D), and advance the many European-sponsored TB vaccine candidates currently in the development pipeline. Outlining EU-wide and country-specific funding targets, and examples of successful initiatives thus far, this proposal offers ambitious and realistic guidelines for creating a TB-free future.
To download the brief, click here.
For more TB news, check out the latest edition of the TB Online Weekly Newsletter.
Source : Treatment Action Group
Related HIV and Co-Infections News
-
Eastleigh Voice: Ghana rejects Sh14 billion US health deal over data access concerns
-
The Lancet Global Health: Untangling the complex relationship between HIV-exposure and TB in children: A narrative review
-
Research Centre Borstel: Long-term cure rates for multidrug-resistant TB much better than expected
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.